Semax and Selank are frequently mentioned in the same breath. Both are stabilized heptapeptides developed through Russian neuropharmacology programs, both carry the same Pro-Gly-Pro stabilizing tail, and both are staples of preclinical neuroscience catalogs. But their research profiles diverge sharply, and a laboratory choosing between them should understand why.
A Shared Origin
Both peptides came out of the Institute of Molecular Genetics in Moscow, where researchers in the 1980s and 1990s were looking for ways to make short, biologically active peptide fragments last long enough in the body to study. Native fragments of hormones are cleared in minutes. The solution the group settled on was to attach a Pro-Gly-Pro tripeptide to the C-terminus, which protects the sequence from the enzymes that normally chew it up. Semax and Selank are the two best-known products of that approach, built from two different parent molecules.
Semax: The Neurotrophic Probe
Semax derives from the ACTH(4-10) fragment of adrenocorticotropic hormone (Met-Glu-His-Phe-Pro-Gly-Pro), stripped of hormonal activity and stabilized for research use. It retains no effect on cortisol release, which is what distinguishes it from its parent.
The literature clusters around brain-derived neurotrophic factor. Rodent studies report increased BDNF and TrkB receptor expression in the hippocampus within hours of administration, and gene-expression studies have mapped broad changes in neurotrophin and immune-related transcripts in the brain. A second thread examines the melanocortin system: ACTH-derived fragments interact with central melanocortin receptors, and several papers propose this as a route for Semax’s effects on attention and learning endpoints in animal models. A third thread, from stroke and ischemia models, reports reduced lesion size and preserved function, which is where the neuroprotection claims come from. When a study design needs a neurotrophic or attention-related probe, Semax is typically the choice.
Selank: The Anxiolytic-Focused Analog
Selank is built instead from tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) released from immunoglobulin G that stimulates phagocytes. Adding Pro-Gly-Pro gives the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Its research profile centers on anxiety-related behavioral models (elevated plus maze, open field, and similar assays), where it is compared against benzodiazepine reference compounds. Mechanistic work points in two directions: modulation of GABA-A receptor signaling, with studies reporting that Selank alters the receptor’s response to GABA and changes expression of GABA-related genes; and effects on monoamine turnover, particularly serotonin and dopamine in specific brain regions. Because tuftsin is an immune peptide, Selank also has an immunology literature covering cytokine expression, particularly interleukin-6 and the Th1/Th2 balance, which places it in a distinctive niche where immunology meets behavioral neuroscience. Studies also report that Selank slows the breakdown of enkephalins, the brain’s endogenous opioid peptides, which may contribute to its behavioral profile.
Structural Cousins, Different Questions
The shared Pro-Gly-Pro extension gives both peptides their stability, but the parent molecules define the research: an ACTH fragment points Semax toward neurotrophic and melanocortin signaling, while a tuftsin backbone points Selank toward GABAergic, monoamine, and neuroimmune pathways. They are complements rather than substitutes.
| Semax | Selank | |
|---|---|---|
| Parent molecule | ACTH(4-10) | Tuftsin |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Primary research endpoints | BDNF/TrkB expression, attention and memory models, ischemia models | Anxiety-related behavior, GABA-A modulation, cytokine expression |
| Receptor systems studied | Melanocortin, neurotrophin | GABAergic, monoamine, opioid peptide metabolism |
| Oxidation-sensitive residue | Methionine (position 1) | None |
What the Literature Does Not Settle
Both peptides share a limitation: the research base is concentrated in Russian institutes and journals, with limited independent replication in Western laboratories. Neither has a definitively identified primary receptor. Semax’s melanocortin interaction and Selank’s GABA-A modulation are the leading hypotheses, but both are inferred from downstream effects rather than direct binding studies in most papers. Laboratories designing mechanistic work should treat these as open questions and build in appropriate controls.
Studying Them Together
Because the profiles are complementary, some laboratories run both compounds within a program. Our Selank + Semax combination supplies the pair in a single research preparation, while individual vials support single-compound designs. Related cognition-focused compounds like Dihexa, which acts through the HGF/c-Met pathway rather than neuropeptide signaling, round out the Neuropeptide Research collection; see our Dihexa overview for the contrast. For blends generally, see Peptide Blends Explained.
Handling Notes
Semax begins with a methionine, which is prone to oxidation to methionine sulfoxide in solution and on exposure to air. Reconstituted Semax should be refrigerated, protected from light, and used promptly; a Certificate of Analysis for Semax should show a mass near 813.4 Da, and a +16 Da peak indicates oxidized material. Selank (about 751.9 Da) has no oxidation-prone residues and is more forgiving. Both are supplied lyophilized; see Storing Lyophilized Peptides and Reconstitution Basics.
Material Quality in Neuropeptide Research
CNS-focused studies are especially sensitive to impurities, because many short-peptide impurities are themselves neuroactive. Every Pristine Aminos neuropeptide batch is independently tested at 99%+ purity and ships with a Certificate of Analysis; see What a COA Tells You.
All products discussed are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.



